comparemela.com

Latest Breaking News On - Ix biopharma ltd - Page 1 : comparemela.com

iX Biopharma Targets Diabetes with New Wafer

iX Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd is developing a new sublingual semaglutide wafer, iXB 401, aimed at treating di.

Ix biopharma ltdReaking news

MeltMed® Rings in the Holidays with Reduced Pricing and New NAD+ Starter Packs

Begin your Wellness Journey with Regenerate Starter Packs;Scientifically formulated to maximise effectiveness of NAD supplement;Enjoy savings of 50%NEW YORK, Dec. 4, 2023 /PRNewswire/ MeltMed®, an innovative

Megan jewettIx biopharma ltdTherapeutic goods administrationBusiness developmentSingapore exchange securities tradingWellness journeyRegenerate starter packsRadiance glutathioneStarter packsRegenerate starter packBusiness development managerCurrent good manufacturing practice

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesNew yorkHong kongRaj mehraGeddy leeX biopharma waferiEuropean medicines agencySeelos therapeutics incDrug administrationSingapore exchange securities trading limitedIx biopharma ltdSeelos therapeutics inc nasdaqSeelos therapeuticsScientific adviceComplex regional pain syndromeLicensed products

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Hong kongNew yorkUnited statesRaj mehraGeddy leeAnthony marcianoIx biopharmaPrnewswire seelos therapeutics incSeelos therapeutics incDrug administrationExchange commissionSingapore exchange securities trading limitedIx biopharma ltdLicense agreementComplex regional pain syndromeOrphan drug

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

/PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central.

Hong kongNew yorkUnited statesRaj mehraGeddy leeAnthony marcianoExchange commissionIx biopharmaSeelos therapeutics incDrug administrationSingapore exchange securities trading limitedIx biopharma ltdSeelos therapeuticsLicense agreementComplex regional pain syndromeOrphan drug

vimarsana © 2020. All Rights Reserved.